div-1 Antibody

Structure of the 2D1 Antibody

The 2D1 antibody is a human IgG1/λ monoclonal antibody derived from a survivor of the 1918 influenza pandemic . Key structural features include:

• Heavy chain: Encoded by the V_H2-70 gene segment with a 9-bp insertion in framework region 3 (FR3) near complementarity-determining region H2 (CDR H2) .

• Light chain: λ-chain with variable domains contributing to antigen binding.

The insertion creates a structural bulge in CDR H2, altering the antigen-binding site’s conformation. Removal of this insertion (del 2D1) reverts the CDR loops to a canonical configuration .

Antigen Binding and Neutralization

The 2D1 antibody targets the Sa antigenic site of the hemagglutinin (HA) protein in influenza viruses. Its deletion variant (del 2D1) shows reduced functional activity:

The deletion variant’s reduced efficacy highlights the critical role of the FR3 insertion in maintaining structural integrity for high-affinity antigen binding .

Mechanism of Action

• Structural Impact: The 9-bp insertion in wt 2D1 reconfigures CDR H1 and H2 loops, enhancing interactions with conserved epitopes in the HA Sa site of pandemic H1N1 strains .

• Developmental Origin: The insertion arose via somatic hypermutation, including point mutations and polymerase slippage during B-cell maturation .

Clinical and Therapeutic Relevance

• Cross-Reactivity: wt 2D1 neutralizes both 1918 and 2009 H1N1 pandemic viruses due to epitope conservation in HA .

• Therapeutic Potential: In murine models, wt 2D1 demonstrated superior in vivo protection compared to del 2D1, underscoring its utility in pandemic preparedness .

Research Implications

The 2D1 antibody study provides insights into:

• Somatic Hypermutation: How insertions/deletions diversify antibody repertoires.

• Antibody Engineering: Structural modifications (e.g., CDR loop stabilization) to enhance therapeutic efficacy.